Do analysts rate ADCT or VIRI?

ADC Therapeutics currently has a consensus price target of $6.25, indicating a potential upside of 418.67%. Given ADC Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe ADC Therapeutics is more favorable than Virios Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ADC Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media refer more to ADCT or VIRI?

In the previous week, ADC Therapeutics had 3 more articles in the media than Virios Therapeutics. MarketBeat recorded 4 mentions for ADC Therapeutics and 1 mentions for Virios Therapeutics. ADC Therapeutics' average media sentiment score of 0.10 beat Virios Therapeutics' score of 0.00 indicating that ADC Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADC Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Virios Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer SPRO or VIRI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media refer more to SPRO or VIRI?

In the previous week, Spero Therapeutics had 1 more articles in the media than Virios Therapeutics. MarketBeat recorded 2 mentions for Spero Therapeutics and 1 mentions for Virios Therapeutics. Spero Therapeutics' average media sentiment score of 0.30 beat Virios Therapeutics' score of 0.00 indicating that Spero Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spero Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Virios Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer VIRI or GNLX?

Genelux has a consensus target price of $18.00, suggesting a potential upside of 502.01%. Given Genelux's stronger consensus rating and higher probable upside, analysts clearly believe Genelux is more favorable than Virios Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Genelux 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is VIRI or GNLX more profitable?

Virios Therapeutics' return on equity of -130.33% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Virios Therapeutics N/A -130.33% -115.00% Genelux N/A -174.55% -123.65%

Does the media prefer VIRI or GNLX?

In the previous week, Genelux had 3 more articles in the media than Virios Therapeutics. MarketBeat recorded 4 mentions for Genelux and 1 mentions for Virios Therapeutics. Genelux's average media sentiment score of 0.20 beat Virios Therapeutics' score of 0.00 indicating that Genelux is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Virios Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genelux 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CUE or VIRI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer VIRI or PLYX?

Polaryx Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 255.87%. Given Polaryx Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Polaryx Therapeutics is more favorable than Virios Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Polaryx Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation and earnings, VIRI or PLYX?

Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Virios Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virios Therapeutics N/A N/A -$5.30M -$0.27 N/A Polaryx Therapeutics N/A N/A N/A -$0.05 N/A

Is VIRI or PLYX more profitable?

Polaryx Therapeutics' return on equity of 0.00% beat Virios Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Virios Therapeutics N/A -130.33% -115.00% Polaryx Therapeutics N/A N/A N/A

Virios Therapeutics (VIRI) Competitors

$1.49 -0.01 (-0.67%)

As of 07/2/2026

Compare

VIRI vs. ADCT, SPRO, GNLX, CUE, and PLYX

Should you buy Virios Therapeutics stock or one of its competitors? MarketBeat compares Virios Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Virios Therapeutics include ADC Therapeutics (ADCT), Spero Therapeutics (SPRO), Genelux (GNLX), Cue Biopharma (CUE), and Polaryx Therapeutics (PLYX). These companies are all part of the "pharmaceutical products" industry.

How does Virios Therapeutics compare to ADC Therapeutics?

ADC Therapeutics (NYSE:ADCT) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

41.1% of ADC Therapeutics shares are held by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are held by institutional investors. 5.4% of ADC Therapeutics shares are held by company insiders. Comparatively, 12.2% of Virios Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

ADC Therapeutics has a beta of 1.87, meaning that its share price is 87% more volatile than the broader market. Comparatively, Virios Therapeutics has a beta of 1.58, meaning that its share price is 58% more volatile than the broader market.

In the previous week, ADC Therapeutics had 3 more articles in the media than Virios Therapeutics. MarketBeat recorded 4 mentions for ADC Therapeutics and 1 mentions for Virios Therapeutics. ADC Therapeutics' average media sentiment score of 0.10 beat Virios Therapeutics' score of 0.00 indicating that ADC Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADC Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Virios Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ADC Therapeutics currently has a consensus price target of $6.25, indicating a potential upside of 418.67%. Given ADC Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe ADC Therapeutics is more favorable than Virios Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Virios Therapeutics has lower revenue, but higher earnings than ADC Therapeutics. Virios Therapeutics is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADC Therapeutics	$81.36M	1.88	-$142.62M	-$1.05	N/A
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A

Virios Therapeutics has a net margin of 0.00% compared to ADC Therapeutics' net margin of -173.02%. ADC Therapeutics' return on equity of 0.00% beat Virios Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADC Therapeutics	-173.02%	N/A	-44.70%
Virios Therapeutics	N/A	-130.33%	-115.00%

Summary

ADC Therapeutics beats Virios Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Virios Therapeutics compare to Spero Therapeutics?

Spero Therapeutics (NASDAQ:SPRO) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

25.6% of Spero Therapeutics shares are owned by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are owned by institutional investors. 2.9% of Spero Therapeutics shares are owned by company insiders. Comparatively, 12.2% of Virios Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Spero Therapeutics has a net margin of 24.90% compared to Virios Therapeutics' net margin of 0.00%. Spero Therapeutics' return on equity of 35.58% beat Virios Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spero Therapeutics	24.90%	35.58%	24.95%
Virios Therapeutics	N/A	-130.33%	-115.00%

Spero Therapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market. Comparatively, Virios Therapeutics has a beta of 1.58, indicating that its share price is 58% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spero Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Spero Therapeutics has higher revenue and earnings than Virios Therapeutics. Virios Therapeutics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spero Therapeutics	$54.77M	2.33	$8.57M	$0.24	9.17
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A

In the previous week, Spero Therapeutics had 1 more articles in the media than Virios Therapeutics. MarketBeat recorded 2 mentions for Spero Therapeutics and 1 mentions for Virios Therapeutics. Spero Therapeutics' average media sentiment score of 0.30 beat Virios Therapeutics' score of 0.00 indicating that Spero Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spero Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Virios Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Spero Therapeutics beats Virios Therapeutics on 11 of the 13 factors compared between the two stocks.

How does Virios Therapeutics compare to Genelux?

Virios Therapeutics (NASDAQ:VIRI) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

Virios Therapeutics' return on equity of -130.33% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virios Therapeutics	N/A	-130.33%	-115.00%
Genelux	N/A	-174.55%	-123.65%

Genelux has a consensus target price of $18.00, suggesting a potential upside of 502.01%. Given Genelux's stronger consensus rating and higher probable upside, analysts clearly believe Genelux is more favorable than Virios Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Genelux had 3 more articles in the media than Virios Therapeutics. MarketBeat recorded 4 mentions for Genelux and 1 mentions for Virios Therapeutics. Genelux's average media sentiment score of 0.20 beat Virios Therapeutics' score of 0.00 indicating that Genelux is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Virios Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genelux	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Virios Therapeutics has higher earnings, but lower revenue than Genelux. Virios Therapeutics is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A
Genelux	$10K	13,407.16	-$32.15M	-$0.85	N/A

9.1% of Virios Therapeutics shares are held by institutional investors. Comparatively, 37.3% of Genelux shares are held by institutional investors. 12.2% of Virios Therapeutics shares are held by company insiders. Comparatively, 7.5% of Genelux shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Virios Therapeutics has a beta of 1.58, indicating that its share price is 58% more volatile than the broader market. Comparatively, Genelux has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market.

Summary

Genelux beats Virios Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Virios Therapeutics compare to Cue Biopharma?

Cue Biopharma (NASDAQ:CUE) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Cue Biopharma has a beta of 2.45, suggesting that its share price is 145% more volatile than the broader market. Comparatively, Virios Therapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the broader market.

35.0% of Cue Biopharma shares are held by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are held by institutional investors. 14.6% of Cue Biopharma shares are held by company insiders. Comparatively, 12.2% of Virios Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Virios Therapeutics has a net margin of 0.00% compared to Cue Biopharma's net margin of -59.65%. Cue Biopharma's return on equity of -98.30% beat Virios Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-59.65%	-98.30%	-53.69%
Virios Therapeutics	N/A	-130.33%	-115.00%

Virios Therapeutics has lower revenue, but higher earnings than Cue Biopharma. Virios Therapeutics is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$32.73M	3.63	-$26.60M	-$5.58	N/A
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Virios Therapeutics had 1 more articles in the media than Cue Biopharma. MarketBeat recorded 1 mentions for Virios Therapeutics and 0 mentions for Cue Biopharma. Cue Biopharma's average media sentiment score of 0.00 equaled Virios Therapeutics'average media sentiment score.

Company	Overall Sentiment
Cue Biopharma	Neutral
Virios Therapeutics	Neutral

Summary

Cue Biopharma beats Virios Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Virios Therapeutics compare to Polaryx Therapeutics?

Virios Therapeutics (NASDAQ:VIRI) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

Polaryx Therapeutics' return on equity of 0.00% beat Virios Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virios Therapeutics	N/A	-130.33%	-115.00%
Polaryx Therapeutics	N/A	N/A	N/A

In the previous week, Virios Therapeutics had 1 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 1 mentions for Virios Therapeutics and 0 mentions for Polaryx Therapeutics. Virios Therapeutics' average media sentiment score of 0.00 equaled Polaryx Therapeutics'average media sentiment score.

Company	Overall Sentiment
Virios Therapeutics	Neutral
Polaryx Therapeutics	Neutral

9.1% of Virios Therapeutics shares are held by institutional investors. 12.2% of Virios Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Polaryx Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 255.87%. Given Polaryx Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Polaryx Therapeutics is more favorable than Virios Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Polaryx Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Virios Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A
Polaryx Therapeutics	N/A	N/A	N/A	-$0.05	N/A

Summary

Polaryx Therapeutics beats Virios Therapeutics on 6 of the 10 factors compared between the two stocks.

Get Virios Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VIRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VIRI vs. The Competition

Export

Metric	Virios Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$28.69M	$791.45M	$7.16B	$12.48B
Dividend Yield	N/A	4.84%	2.66%	6.52%
P/E Ratio	-5.52	1.66	28.02	24.70
Price / Sales	N/A	127.11	540.37	99.49
Price / Cash	N/A	20.06	49.26	57.09
Price / Book	7.45	8.17	10.96	6.46
Net Income	-$5.30M	-$3.71M	$3.57B	$337.01M
7 Day Performance	-9.70%	2.59%	2.12%	1.69%
1 Month Performance	-11.31%	4.41%	5.25%	3.81%
1 Year Performance	-68.96%	49.43%	33.29%	23.90%

Virios Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VIRI Virios Therapeutics	N/A	$1.49 -0.7%	N/A	-69.0%	$28.69M	N/A	N/A	5	Gap Up
ADCT ADC Therapeutics	3.1833 of 5 stars	$1.06 +2.4%	$6.25 +492.4%	-56.8%	$131.01M	$81.36M	N/A	310	Gap Down
SPRO Spero Therapeutics	1.5585 of 5 stars	$2.21 -2.2%	N/A	-24.4%	$130.86M	$66.80M	9.21	150
GNLX Genelux	1.895 of 5 stars	$3.01 +3.8%	$18.00 +498.0%	+0.3%	$130.04M	$10K	N/A	10	News Coverage Gap Up
CUE Cue Biopharma	0.1738 of 5 stars	$31.56 +3.7%	N/A	-95.4%	$127.82M	$27.47M	N/A	60	Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VIRI) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Virios Therapeutics (VIRI) Competitors

VIRI vs. ADCT, SPRO, GNLX, CUE, and PLYX

How does Virios Therapeutics compare to ADC Therapeutics?

Summary

How does Virios Therapeutics compare to Spero Therapeutics?

Summary

How does Virios Therapeutics compare to Genelux?

Summary

How does Virios Therapeutics compare to Cue Biopharma?

Summary

How does Virios Therapeutics compare to Polaryx Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIRI vs. The Competition

Virios Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Virios Therapeutics (VIRI) Competitors

VIRI vs. ADCT, SPRO, GNLX, CUE, and PLYX

How does Virios Therapeutics compare to ADC Therapeutics?

Do institutionals and insiders believe in ADCT or VIRI?

Which has more volatility and risk, ADCT or VIRI?

Does the media refer more to ADCT or VIRI?

Do analysts rate ADCT or VIRI?

Which has stronger valuation and earnings, ADCT or VIRI?

Is ADCT or VIRI more profitable?

Summary

How does Virios Therapeutics compare to Spero Therapeutics?

Do institutionals and insiders have more ownership in SPRO or VIRI?

Is SPRO or VIRI more profitable?

Which has more risk & volatility, SPRO or VIRI?

Do analysts prefer SPRO or VIRI?

Which has higher valuation & earnings, SPRO or VIRI?

Does the media refer more to SPRO or VIRI?

Summary

How does Virios Therapeutics compare to Genelux?

Is VIRI or GNLX more profitable?

Do analysts prefer VIRI or GNLX?

Does the media prefer VIRI or GNLX?

Which has preferable earnings and valuation, VIRI or GNLX?

Do insiders & institutionals hold more shares of VIRI or GNLX?

Which has more risk & volatility, VIRI or GNLX?

Summary

How does Virios Therapeutics compare to Cue Biopharma?

Which has more volatility and risk, CUE or VIRI?

Do institutionals & insiders hold more shares of CUE or VIRI?

Is CUE or VIRI more profitable?

Which has higher earnings & valuation, CUE or VIRI?

Do analysts prefer CUE or VIRI?

Does the media favor CUE or VIRI?

Summary

How does Virios Therapeutics compare to Polaryx Therapeutics?

Is VIRI or PLYX more profitable?

Does the media refer more to VIRI or PLYX?

Do insiders and institutionals hold more shares of VIRI or PLYX?

Do analysts prefer VIRI or PLYX?

Which has higher valuation and earnings, VIRI or PLYX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VIRI vs. The Competition

Virios Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools